DNTH Overview

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.

Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is77.00 USD with a low forecast of 46.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Dianthus Therapeutics Inc revenue for the last quarter amounts to 463.00K USD, decreased -60.19

Dianthus Therapeutics Inc. EPS for the last quarter amounts to -0.85 USD, increased 3.66

Dianthus Therapeutics Inc (DNTH) has 92 emplpoyees as of June 21 2026.

Today DNTH has the market capitalization of 4.51B USD.